KYMR - Kymera Therapeutics, Inc.

83.52
-2.590   -3.101%

Share volume: 1,044,442
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$86.11
-2.59
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 35%
Dept financing 22%
Liquidity 58%
Performance 31%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.30%
1 Month
4.94%
3 Months
-11.43%
6 Months
93.07%
1 Year
156.67%
2 Year
99.33%
Key data
Stock price
$83.52
P/E Ratio 
0.00
DAY RANGE
$81.50 - $86.92
EPS 
-$3.63
52 WEEK RANGE
$19.44 - $103.00
52 WEEK CHANGE
$153.94
MARKET CAP 
5.598 B
YIELD 
N/A
SHARES OUTSTANDING 
81.642 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
1.94
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,050,847
AVERAGE 30 VOLUME 
$904,446
Company detail
CEO: Nello Mainolfi
Region: US
Website: kymeratx.com
Employees: 170
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Kymera Therapeutics, Inc. focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases. IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the. treatment of hematologic malignancies and solid tumors.

Recent news